Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients
Open Access
- 29 May 2008
- journal article
- research article
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 23 (11), 3605-3612
- https://doi.org/10.1093/ndt/gfn304
Abstract
Background. Hypertensive haemodialysis patients may be at a high risk for cardiovascular events. This study was undertaken to ascertain whether the calcium channel blocker amlodipine reduces mortality and cardiovascular events in these high-risk patients. Methods. We evaluated the effects of amlodipine on cardiovascular events in 251 hypertensive haemodialysis patients in an investigator-designed, prospective, randomized, double-blind, placebo-controlled, multicenter trial. One hundred and twenty-three patients were randomly assigned to amlodipine (10 mg once daily) and 128 to placebo. The primary endpoint was mortality from any cause. The secondary endpoint was a composite variable consisting of mortality from any cause or cardiovascular event. Analysis was by intention-to-treat. The trial was registered with ClinicalTrials.gov (number NCT00124969). Results. The median age of patients was 61 years (25% percentile − 75% percentile, 47–69), and the median follow-up was 19 months (8–30). Fifteen (12%) of the 123 patients assigned to amlodipine and 22 (17%) of the 128 patients assigned to placebo had a primary endpoint [hazard ratio 0.65 (95% CI 0.34–1.23); P = 0.19]. Nineteen (15%) of the 123 haemodialysis patients assigned to amlodipine and 32 (25%) of the 128 haemodialysis patients assigned to placebo reached the secondary composite endpoint [hazard ratio 0.53 (95% CI 0.31–0.93); P = 0.03]. Conclusion. Amlodipine safely reduces systolic blood pressure and it may have a beneficial effect on cardiovascular outcomes in hypertensive haemodialysis patients.Keywords
This publication has 20 references indexed in Scilit:
- Racial and survival paradoxes in chronic kidney diseaseNature Clinical Practice Nephrology, 2007
- KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney DiseaseAmerican Journal of Kidney Diseases, 2007
- Antihypertensive Therapy in the Presence of ProteinuriaAmerican Journal of Kidney Diseases, 2007
- Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end-stage renal disease patients on hemodialysisKidney International, 2006
- The Epidemiology of Systolic Blood Pressure and Death Risk in Hemodialysis PatientsAmerican Journal of Kidney Diseases, 2006
- Atorvastatin in Patients with Type 2 Diabetes Mellitus Undergoing HemodialysisNew England Journal of Medicine, 2005
- Reverse Epidemiology of Hypertension and Cardiovascular Death in the Hemodialysis PopulationHypertension, 2005
- Calcium channel blocker use and mortality among patients with end-stage renal diseaseKidney International, 2002
- Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal diseaseKidney International, 1996
- Role of systolic blood pressure in determining prognosis of hemodialyzed patientsAmerican Journal of Kidney Diseases, 1995